Selective escalation of imatinib therapy and early switching to nilotinib in de novo chronic phase CML patients: interim results from the TIDELL-II trial
Date
2010
Authors
Yeung, D.
Osborn, M.
White, D.
Branford, S.
Haswell, L.
Slader, C.
Issa, S.
Hiwase, D.
Hertzberg, M.
Schwarer, A.
Editors
Advisors
Journal Title
Journal ISSN
Volume Title
Type:
Conference paper
Citation
Blood, 2010; 116 (21), Abstract 209
Statement of Responsibility
David T. Yeung, Michael Osborn, Deborah L. White, Susan Branford, Lauren Haswell, Cassandra Slader, Samar Issa, Devendra K. Hiwase, Mark S. Hertzberg, Anthony P. Schwarer, Robin Filshie, Christopher K. Arthur, Yiu Lam Kwan, Cecily J. Forsyth, David M. Ross, Anthony K. Mills, Andrew Grigg and Timothy Hughes and on behalf of ALLG
Conference Name
Annual Meeting of the American Society of Hematology (52nd : 2010 : Orlando, Fl.)
Abstract
School/Discipline
Dissertation Note
Provenance
Description
Oral session ASH Annual Meeting Abstracts: 52nd Annual Meeting of the American Society of Hematology (ASH), Orlando, FL, December 4-7, 2010
Access Status
Rights
© 2010 American Society of Hematology